Loading clinical trials...

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis | Clinical Trials | Clareo Health

TERMINATEDPhase 3NCT02258867

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).

Lead sponsor: XOMA (US) LLC•8 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusTERMINATED

PhasePHASE3

Enrollment4

Start dateNov 2014

Last updatedDec 29, 2015

Condition

Behcet's Disease Uveitis

Locations shown

Santa Ana, California

Chicago, Illinois

Ellsworth, Maine

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 29, 2015Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions